Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

被引：0
|
作者：
Edward Sausville
Patricia LoRusso
Michael Carducci
Judith Carter
Mary F. Quinn
Lisa Malburg
Nilofer Azad
David Cosgrove
Richard Knight
Peter Barker
Sonya Zabludoff
Felix Agbo
Patricia Oakes
Adrian Senderowicz
机构：
[1] University of Maryland,Marlene and Stewart Greenebaum Cancer Center
[2] Wayne State University School of Medicine,Karmanos Cancer Center
[3] Johns Hopkins Medical Institutions,Sidney Kimmel Comprehensive Cancer Center
[4] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
AZD7762; Chk1; Solid tumors; Phase I; Safety; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 549
页数：10
相关论文
共 50 条
  • [1] Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
    Sausville, Edward
    LoRusso, Patricia
    Carducci, Michael
    Carter, Judith
    Quinn, Mary F.
    Malburg, Lisa
    Azad, Nilofer
    Cosgrove, David
    Knight, Richard
    Barker, Peter
    Zabludoff, Sonya
    Agbo, Felix
    Oakes, Patricia
    Senderowicz, Adrian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 539 - 549
  • [2] Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
    Sausville, E. A.
    LoRusso, P.
    Carducci, M. A.
    Barker, P. N.
    Agbo, F.
    Oakes, P.
    Senderowicz, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 619 - 627
  • [5] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Takashi Seto
    Taito Esaki
    Fumihiko Hirai
    Shuji Arita
    Kaname Nosaki
    Akitaka Makiyama
    Takuro Kometani
    Chinatsu Fujimoto
    Motoharu Hamatake
    Hiroaki Takeoka
    Felix Agbo
    Xiaojin Shi
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 619 - 627
  • [6] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
    Daud, Adil I.
    Ashworth, Michelle T.
    Strosberg, Jonathan
    Goldman, Jonathan W.
    Mendelson, David
    Springett, Gregory
    Venook, Alan P.
    Loechner, Sabine
    Rosen, Lee S.
    Shanahan, Frances
    Parry, David
    Shumway, Stuart
    Grabowsky, Jennifer A.
    Freshwater, Tomoko
    Sorge, Christopher
    Kang, Soonmo Peter
    Isaacs, Randi
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1060 - +
  • [8] Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
    Makoto Isono
    Michèle J. Hoffmann
    Maria Pinkerneil
    Akinori Sato
    Martin Michaelis
    Jindrich Cinatl
    Günter Niegisch
    Wolfgang A. Schulz
    Journal of Experimental & Clinical Cancer Research, 36
  • [9] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
    Sandrine Aspeslagh
    Kunwar Shailubhai
    Rastilav Bahleda
    Anas Gazzah
    Andréa Varga
    Antoine Hollebecque
    Christophe Massard
    Anna Spreafico
    Michele Reni
    Jean-Charles Soria
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1257 - 1265
  • [10] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Shailubhai, Kunwar
    Bahleda, Rastilav
    Gazzah, Anas
    Varga, Andrea
    Hollebecque, Antoine
    Massard, Christophe
    Spreafico, Anna
    Reni, Michele
    Soria, Jean-Charles
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1257 - 1265
12345